Practical guidance on visualizing the urethra for prostate planning. Citation as given in the eviQ reference list; not yet checked against the journal.
Urethra
Dose constraints
Prostate SBRT
| Schedule | Constraint | Source |
|---|---|---|
| 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V42 Gy ≤0.1 cc (acceptable) | TROG NINJA |
| V40 Gy ≤0.1 cc (ideal) | eviQ 4140 |
Applied to the urethral PRV (urethra + 0.2–0.3 cm).
Quoted from eviQ 4140, checked 2026-09-22. Full table with references →
Anatomy
The prostatic urethra runs through the center of the prostate from the bladder neck to the apex, where it continues as the membranous urethra.
Function in the body
The urethra carries urine from the bladder out of the body; its first part runs through the prostate.
Why it matters
Because the urethra passes through the target, it cannot be avoided — only protected from hotspots. This matters most in prostate SBRT and when boosting a dominant intraprostatic lesion, where high doses per fraction make urinary toxicity more closely tied to how hot the urethra gets. Plans therefore cap the highest dose to the urethra (or a PRV around it) rather than trying to keep it cool.
How to contour
In Richardson 2021 the prostatic urethra was contoured inside the prostate CTV from the bladder neck to the prostate apex, on the sagittal view with a 2 mm brush. Large TURP defects inside the CTV were included. A further 3 mm expansion made a cylindrical urethra PRV.
The study found a thin (0.9 mm), 3D T2-weighted MRI cut variation between observers markedly compared with planning CT or a standard 3 mm T2 scan. The urethra can still need some estimation, so use the method your protocol describes.
Further reading
- TROG NINJA — TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol Source
- PACE-B — Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Source